Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Acumen Pharmaceuticals Inc’s current trading price is -61.15% away from its 52-week high, while its distance from the 52-week low is 63.55%. The stock’s price range during this period has varied between $0.86 and $3.60. The company, active in the Healthcare sector, saw a trading volume of around 3.0 million for the day, considerably higher average daily volume of 0.37 million observed over the last three months.
Acumen Pharmaceuticals Inc (ABOS) currently has a stock price of $1.4. The stock saw a sharp increase in the last trading session, hitting a high of $11.0 after opening at $1.39. The lowest recorded price for the day was $4.0 before it closed at $1.49.
The market performance of Acumen Pharmaceuticals Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $3.60 on 07/29/24, with the lowest value for the same timeframe being $0.86, recorded on 04/21/25.
How Financial Performance Impacts Market Capitalization
Acumen Pharmaceuticals Inc (ABOS) has experienced a quarterly rise of 25.99% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 84.71M and boasts a workforce of 61 employees.
Decoding Analysts’ Ratings for Acumen Pharmaceuticals Inc
As of right now, 6 analysts are rating Acumen Pharmaceuticals Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.1415, with a change in price of -0.0500. Similarly, Acumen Pharmaceuticals Inc recorded 338,856 in trading volume during the last 100 days, posting a change of -3.57%.
How ABOS’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ABOS stands at 0.19. Similarly, the long-term debt-to-equity ratio is also 0.19.
ABOS Stock Stochastic Average
As of today, the raw stochastic average of Acumen Pharmaceuticals Inc over the last 50 days is at 72.29%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 66.67%. Further, the company’s Stochastic %K and %D values for the last 20 days were 82.59% and 86.04%, respectively.
ABOS Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a loss of -46.62%.However, over the last six months, we can see a stronger performance of -15.24%. Over the last 30 days, the price of ABOS has fallen by 22.68%. And in the last five days, it has surged by 15.58%.
